PlexusDx guidance on preparation and administration helps maximize medication effectiveness from day one
Current allegations in the GLP-1 litigation commonly involve claims that: manufacturers failed to provide adequate warnings about delayed gastric emptying and severe gastrointestinal injury risks GLP-1 drugs may cause gastroparesis, ileus, or intestinal obstruction in certain patients patients were not properly informed of the potential side effects beyond common nausea and appetite suppression warning labels did not clearly reflect the risk of long-term digestive dysfunction some patients experienced permanent or prolonged impairment after discontinuing the medication the drugs were marketed in ways that downplayed serious adverse outcomes These allegations are not limited to Victoza, but Victoza has become part of this broader litigation because its mechanism of action overlaps with other GLP-1 medications now facing coordinated claims
Under DWPE, FDA doesnt need to open each shipment or run its own lab tests to hold product
Residual activity on VAMP1 (residues 2888), however, highlighted the need for negative selection (Extended Data Fig
This study will evaluate how our natural, biomimetic GLP-1 peptide may influence sleep patterns, recovery signals, and other biometric markers, and how quickly those changes may appear